Improved granulocyte colony-stimulating factor mobilization of hemopoietic progenitors using cytokine combinations in primates

Stem Cells
Stephen R LarsenJohn E J Rasko

Abstract

Peripheral blood stem cells (PBSCs), usually mobilized with granulocyte colony-stimulating factor (G-CSF) alone or in combination with chemotherapy, are the preferred source of cells for hemopoietic stem cell transplantation. Up to 25% of otherwise eligible transplant recipients fail to harvest adequate PBSCs. Therefore it is important to investigate existing and novel reagents to improve PBSC mobilization. Because of marked interindividual variation in humans, we developed a robust nonhuman primate model that allows the direct comparison of the efficacy of two PBSC mobilization regimens within the same animal. Using this model, we compared pegylated G-CSF (pegG-CSF) with standard G-CSF and compared the combination of G-CSF and pegylated megakaryocyte growth and development factor (pegMGDF) with G-CSF plus stem cell factor (SCF) by measuring the levels of CD34(+) cells, colony-forming cells (CFCs), and SCID repopulating cells (SRCs) before and after cytokine administration. Mobilization of CD34(+) cells, CFCs and SRCs using pegG-CSF achieved similar levels to those resulting from 5 days of standard G-CSF. The combination of G-CSF+pegMGDF mobilized progenitors to levels similar to G-CSF+SCF but greater than standard G-CSF for CD...Continue Reading

References

Sep 19, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A BrownJ DiPersio
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A WeaverD Crowther
Aug 14, 2002·Cancer Treatment Reviews·S L Yowell, S Blackwell
Nov 19, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·James L GajewskiRichard Champlin
Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M D GreenUNKNOWN International Pegfilgrastim 749 Study Group
Jun 19, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Charles LinkerCharles Weaver
Dec 25, 2003·Cytokine·Virginia C Broudy, Nancy L Lin
Dec 14, 2004·Clinical Pharmacology and Therapeutics·Bing WangJohn T Sullivan
Feb 17, 2006·European Journal of Haematology·Lara MalerbaGiuseppe Visani
Jun 2, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Geoffrey R HillSimon Durrant
Nov 30, 2007·The New England Journal of Medicine·James B BusselJulian M Jenkins

❮ Previous
Next ❯

Citations

Aug 18, 2010·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Deyu DuanZhewei Ye
Sep 17, 2011·Pathology·L Bik ToIan D Lewis
Nov 7, 2012·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Jean-Pierre LevesqueJohn E J Rasko
Apr 10, 2019·Blood Cancer Journal·Rama Al HamedMohamad Mohty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.